• Title of article

    Chronic Graft versus Host Disease after Allogeneic Bone Marrow Transplantation; An Analysis of Incidence and Risk Factors.

  • Author/Authors

    Ghavamzadeh، A نويسنده Hematology- Oncology and BMT Research Center, Shariati Hospital, Tehran, Iran Ghavamzadeh, A , Alimoghaddam، K نويسنده Hematology- Oncology and BMT Research Center, Shariati Hospital, Tehran, Iran Alimoghaddam, K , Bahar، B نويسنده Hematology- Oncology and BMT Research Center, Shariati Hospital, Tehran, Iran Bahar, B , Foroughi، F نويسنده Hematology- Oncology and BMT Research Center, Shariati Hospital, Tehran, Iran Foroughi, F

  • Issue Information
    دوفصلنامه با شماره پیاپی 0 سال 2004
  • Pages
    4
  • From page
    16
  • To page
    19
  • Abstract
    Background: Chronic graft versus host disease (cGVHD) is one of the most serious potential complications of allogeneic bone marrow transplantation.
    Study design and method: We analyzed the incidence of cGVHD and its associated risk factors in a group of 161 Iranian recipients of HLA-identical sibling transplants, with at least 90 days post-transplantation survival. In the majority of cases (n=73), cGVHD occurred in the first year after the transplant (median 273 days). The actual probability of cGVHD within 1 year was 45.3±7% (CI 95%).
    Results:
    In a univariate analysis, the most important risk factor was the type of transplant. Peripheral blood stem cell transplants (PBSCT) showed a significant increase in cGVHD compared with bone marrow transplants (BMT) (RR=2.34, p<0.001). In addition, male recipients were at a greater risk than female recipients (RR=2.08, p=0.004). Other risk factors were the presence of prior acute GVHD (RR=2.37, p=0.04) and the previous acute GVHD grade (p=0.03); The probabilities of cGV D in patients with grade 0, Ι, ΙІ, ΙΙΙ, ΙV acute GVHD were 24%, 44.7%, 42.6%, 56.8%, 64.3%, respectively.
    Conclusion: In a multivariate analysis, the only independent predictive factors for the development of cGVHD were the type of transplant (PBSC>BM, p<0.001) and male recipient (p=0.005). The survival rate was 88.8% and there was no significant difference in the probability of survival between BPSCT vs BMT (93.8% vs 86.6%, p=0.5).
  • Journal title
    International Journal of Hematology-Oncology and Stem Cell Research (IJHOSCR)
  • Serial Year
    2004
  • Journal title
    International Journal of Hematology-Oncology and Stem Cell Research (IJHOSCR)
  • Record number

    2394011